Jakob Kaminski1, Tobias Gleich2, Yu Fukuda2, Teresa Katthagen2, Jürgen Gallinat3, Andreas Heinz2, Florian Schlagenhauf4. 1. Department of Psychiatry and Psychotherapy Charité Campus Mitte, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany. Electronic address: jakob.kaminski@charite.de. 2. Department of Psychiatry and Psychotherapy Charité Campus Mitte, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany. 3. University Clinic Hamburg-Eppendorf, Clinic and Policlinic for Psychiatry and Psychotherapy, Hamburg, Germany. 4. Department of Psychiatry and Psychotherapy Charité Campus Mitte, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; Bernstein Center for Computational Neuroscience, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Abstract
BACKGROUND: Cognitive deficits such as working memory (WM) impairment are core features of schizophrenia. One candidate marker for the integrity of synaptic neurotransmission necessary for cognitive processes is glutamate. It is frequently postulated that antipsychotic medication possibly alters functional mechanisms in the living brain. We tested in vivo for group differences in activation of the dorsolateral prefrontal cortex (DLPFC) during WM performance and the association with glutamate concentration in DLPFC depending on medication status. METHODS: A total of 90 subjects (35 control subjects, 36 medicated patients, and 19 unmedicated patients) contributed magnetic resonance spectroscopy data. We estimated glutamate in left DLPFC. Subjects performed an n-back WM task (2-back vs. 0-back) during functional magnetic resonance imaging, and local activation in left DLPFC was measured. For analysis of association with medication status, we calculated linear regression models including an interaction effect with group. RESULTS: Medicated and unmedicated patients with schizophrenia showed impaired performance. We found significantly reduced WM activation in left DLPFC in medicated patients and a trendwise reduction in unmedicated patients as compared with control subjects. We found no group difference in local glutamate concentration. However, we found differential effects of medication status on the association between local glutamate concentration and WM activation in left DLPFC, with a positive association in unmedicated patients but not in medicated patients. CONCLUSIONS: We provide evidence that WM-dependent activation is associated with glutamate concentration in unmedicated patients with schizophrenia. Our finding points to putative allostatic changes that affect the functioning of the brain and might be altered through medication.
BACKGROUND:Cognitive deficits such as working memory (WM) impairment are core features of schizophrenia. One candidate marker for the integrity of synaptic neurotransmission necessary for cognitive processes is glutamate. It is frequently postulated that antipsychotic medication possibly alters functional mechanisms in the living brain. We tested in vivo for group differences in activation of the dorsolateral prefrontal cortex (DLPFC) during WM performance and the association with glutamate concentration in DLPFC depending on medication status. METHODS: A total of 90 subjects (35 control subjects, 36 medicated patients, and 19 unmedicated patients) contributed magnetic resonance spectroscopy data. We estimated glutamate in left DLPFC. Subjects performed an n-back WM task (2-back vs. 0-back) during functional magnetic resonance imaging, and local activation in left DLPFC was measured. For analysis of association with medication status, we calculated linear regression models including an interaction effect with group. RESULTS: Medicated and unmedicated patients with schizophrenia showed impaired performance. We found significantly reduced WM activation in left DLPFC in medicated patients and a trendwise reduction in unmedicated patients as compared with control subjects. We found no group difference in local glutamate concentration. However, we found differential effects of medication status on the association between local glutamate concentration and WM activation in left DLPFC, with a positive association in unmedicated patients but not in medicated patients. CONCLUSIONS: We provide evidence that WM-dependent activation is associated with glutamate concentration in unmedicated patients with schizophrenia. Our finding points to putative allostatic changes that affect the functioning of the brain and might be altered through medication.
Authors: Ji Chen; Veronika I Müller; Juergen Dukart; Felix Hoffstaedter; Justin T Baker; Avram J Holmes; Deniz Vatansever; Thomas Nickl-Jockschat; Xiaojin Liu; Birgit Derntl; Lydia Kogler; Renaud Jardri; Oliver Gruber; André Aleman; Iris E Sommer; Simon B Eickhoff; Kaustubh R Patil Journal: Biol Psychiatry Date: 2020-10-03 Impact factor: 13.382
Authors: Mark Corcoran; Emma L Hawkins; Denis O'Hora; Heather C Whalley; Jeremy Hall; Stephen M Lawrie; Maria R Dauvermann Journal: Brain Behav Date: 2020-05-09 Impact factor: 2.708
Authors: Kun Yang; Anouk Marsman; Subechhya Pradhan; Jennifer M Coughlin; Min Wang; Rebecca E Ward; Susanne Bonekamp; Emily B Ambinder; Cecilia P Higgs; Pearl K Kim; Jamie A Edwards; Mark Varvaris; Hongxing Wang; Sotirios Posporelis; Shuangchao Ma; Tsuyoshi Tsujimura; Richard A E Edden; Martin G Pomper; Thomas W Sedlak; Margot Fournier; David J Schretlen; Nicola G Cascella; Peter B Barker; Akira Sawa Journal: Mol Psychiatry Date: 2020-10-19 Impact factor: 15.992